Fibrates in the management of atherogenic dyslipidemia

References

• Fredrickson DS, Lees RS. Editorial: a system for phenotyping hyperlipoproteinemia. Circulation. 1965 Mar 1;31:321–327.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Al Qarni A, Hawwari A, et al. Metabolic syndrome, dyslipidemia and regulation of lipoprotein metabolism. Curr Diabetes Rev. 2017 Jul 5;13. DOI: 10.2174/1573399813666170705161039. [Epub ahead of print].
   Google Scholar
• Fruchart J-C, Sacks FM, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diab Vasc Dis Res. 2008 Nov;5:319–335.
   PubMed Web of Science ®Google Scholar
• Reiner Ž. Are elevated serum triglycerides really a risk factor for coronary artery disease? Cardiology. 2015;131:225–227.
   PubMed Web of Science ®Google Scholar
• Reiner Ž. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017 Mar 16;14:401–411.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016 Oct 14;37:2999–3058.
   PubMed Web of Science ®Google Scholar
• Madhu K, Manjunath C, Rawal J, et al. Atherogenic dyslipidemia. Indian J Endocrinol Metab. 2013;17:969.
   PubMedGoogle Scholar
• Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:1–21.
   Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011 Jun;32:1345–1361.
   PubMed Web of Science ®Google Scholar
• Hoogeveen RC, Gaubatz JW, Sun W, et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014 May 1;34:1069–1077.
   PubMed Web of Science ®Google Scholar
• Tall AR. An overview of reverse cholesterol transport. Eur Heart J. 1998 Feb;19 Suppl A:A31–5.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Hermans MP, Fioretto P, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation. 2014 Mar 4;129:999–1008.
   PubMed Web of Science ®Google Scholar
• Reiner Ž. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis. 2013 Sep;23:799–807.
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA, Groen AK. Beyond the genetics of HDL: why is HDL cholesterol inversely related to cardiovascular disease? Handb Exp Pharmacol. 2015;224:285–300.
   PubMedGoogle Scholar
• Lazo-Porras M, Bernabe-Ortiz A, Málaga G, et al. Low HDL cholesterol as a cardiovascular risk factor in rural, urban, and rural-urban migrants: PERU MIGRANT cohort study. Atherosclerosis. 2016;246:36–43.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007 Jul 18;298:299–308.
   PubMed Web of Science ®Google Scholar
• Stamler, J. Clofibrate and niacin in coronary heart disease. JAMA. 1975 Jan 27;231:360–381.
   PubMed Web of Science ®Google Scholar
• Duval C, Chinetti G, Trottein F, et al. The role of PPARs in atherosclerosis. Trends Mol Med. 2002 Sep;8:422–430.
   PubMed Web of Science ®Google Scholar
• Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin. 2002;18:269–276.
   PubMed Web of Science ®Google Scholar
• Belfort R, Berria R, Cornell J, et al. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab. 2010 Feb;95:829–836.
   PubMed Web of Science ®Google Scholar
• Okopień B, Bułdak Ł, Bołdys A. Current and future trends in the lipid lowering therapy. Pharmacol Rep PR. 2016 Aug;68:737–747.
   PubMed Web of Science ®Google Scholar
• Ghani RA, Bin Yaakob I, Wahab NA, et al. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia. J Clin Lipidol. 2013;7:446–453.
   PubMed Web of Science ®Google Scholar
• Shashkin PN, Jain N, Miller YI, et al. Insulin and glucose play a role in foam cell formation and function. Cardiovasc Diabetol. 2006;5:13.
   PubMed Web of Science ®Google Scholar
• Okopień B, Kowalski J, Krysiak R, et al. Monocyte suppressing action of fenofibrate. Pharmacol Rep PR. 2005;57:367–372.
   PubMed Web of Science ®Google Scholar
• Souissi IJ, Billiet L, Cuaz-Pérolin C, et al. Matrix metalloproteinase-12 gene regulation by a PPAR alpha agonist in human monocyte-derived macrophages. Exp Cell Res. 2008 Nov 1;314:3405–3414.
   PubMed Web of Science ®Google Scholar
• Min YJ, Choi YH, Hyeon CW, et al. Fenofibrate reduces C-reactive protein levels in hypertriglyceridemic patients with high risks for cardiovascular diseases. Korean Circ J. 2012;42:741.
   PubMed Web of Science ®Google Scholar
• Kowalski J, Okopień B, Madej A, et al. Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia. Eur J Clin Pharmacol. 2003;59:189–193.
   PubMed Web of Science ®Google Scholar
• Pruski M, Krysiak R, Okopien B. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care. 2009 Aug 1;32:1421–1424.
   PubMed Web of Science ®Google Scholar
• Khera AV, Qamar A, Reilly MP, et al. Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia. Am J Cardiol. 2015 Jan 15;115:178–182.
   PubMed Web of Science ®Google Scholar
• Awazawa M, Ueki K, Inabe K, et al. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab. 2011 Apr 6;13:401–412.
   PubMed Web of Science ®Google Scholar
• Marso SP, Mehta SK, Frutkin A, et al. Low adiponectin levels are associated with atherogenic dyslipidemia and lipid-rich plaque in nondiabetic coronary arteries. Diabetes Care. 2008 May;31:989–994.
   PubMed Web of Science ®Google Scholar
• Tsubakio-Yamamoto K, Matsuura F, Koseki M, et al. Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun. 2008 Oct 24;375:390–394.
   PubMed Web of Science ®Google Scholar
• Tsubakio-Yamamoto K, Sugimoto T, Nishida M, et al. Serum adiponectin level is correlated with the size of HDL and LDL particles determined by high performance liquid chromatography. Metabolism. 2012;61:1763–1770.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Watts GF. Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Atherosclerosis. 2013 Sep;230:110–120.
   PubMed Web of Science ®Google Scholar
• Buldak L, Dulawa-Buldak A, Labuzek K, et al. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose. Int J Clin Pharmacol Ther. 2012 Nov;50:805–813.
   PubMed Web of Science ®Google Scholar
• Willson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000 Feb 24;43:527–550.
   PubMed Web of Science ®Google Scholar
• Tenenbaum A, Fisman EZ. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc Diabetol. 2012;11:140.
   PubMed Web of Science ®Google Scholar
• Remick J, Weintraub H, Setton R, et al. Fibrate therapy: an update. Cardiol Rev. 2008 May;16:129–141.
   PubMed Web of Science ®Google Scholar
• Purohit T, Cappell MS. Primary biliary cirrhosis: pathophysiology, clinical presentation and therapy. World J Hepatol. 2015 May 8;7:926–941.
   PubMedGoogle Scholar
• Vazquez-Carrera M, Roglans N, Sanchez RM, et al. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur J Clin Pharmacol. 2004 Feb 1;59:855–861.
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet Lond Engl. 2005 Nov 26;366:1849–1861.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Armani A, McKenney JM, et al. Safety considerations with fibrate therapy. Am J Cardiol. 2007 Mar 19;99:3C–18C.
   PubMed Web of Science ®Google Scholar
• Kyrklund C, Backman JT, Kivistö KT, et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 2001 May;69:340–345.
   PubMed Web of Science ®Google Scholar
• Tornio A, Neuvonen PJ, Niemi M, et al. Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. Expert Opin Drug Metab Toxicol. 2017 Jan 2;13:83–95.
   PubMed Web of Science ®Google Scholar
• Motawi TK, Teleb ZA, El-Boghdady NA, et al. Effect of simvastatin and naringenin coadministration on rat liver DNA fragmentation and cytochrome P450 activity: an in vivo and in vitro study. J Physiol Biochem. 2014 Mar;70:225–237.
   PubMed Web of Science ®Google Scholar
• Writing Committee, Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016 Jul 5;68:92–125.
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23:1–87.
   PubMed Web of Science ®Google Scholar
• Aguiar C, Alegria E, Bonadonna RC, et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: a report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atheroscler Suppl. 2015 Sep;19:1–12.
   PubMed Web of Science ®Google Scholar
• Reiner Z. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol. 2010 Feb;24(1):19–28.
   PubMed Web of Science ®Google Scholar
• Li X, Gong H, Huang X, et al. The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome. Lipids Health Dis. 2013;12:133.
   PubMed Web of Science ®Google Scholar
• Ebron K, Andersen CJ, Aguilar D, et al. A larger body mass index is associated with increased atherogenic dyslipidemia, insulin resistance, and low-grade inflammation in individuals with metabolic syndrome. Metab Syndr Relat Disord. 2015;13:458–464.
   PubMed Web of Science ®Google Scholar
• Krysiak R, Handzlik G, Okopień B. Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose. Pharmacol Rep PR. 2010 Dec;62:1099–1107.
   PubMed Web of Science ®Google Scholar
• Krysiak R, Gdula-Dymek A, Okopień B. Hemostatic effects of bezafibrate and ω-3 fatty acids in isolated hypertriglyceridemic patients. Pharmacol Rep PR. 2011;63:763–771.
   PubMed Web of Science ®Google Scholar
• Krysiak R, Gdula-Dymek A, Bachowski R, et al. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes Care. 2010 Oct 1;33:2266–2270.
   PubMed Web of Science ®Google Scholar
• Kones R. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag. 2013 Oct;617.
   PubMedGoogle Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317:1237–1245.
   PubMed Web of Science ®Google Scholar
• Frick MH, Heinonen OP, Huttunen JK, et al. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann Med. 1993 Feb;25:41–45.
   PubMed Web of Science ®Google Scholar
• Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998;21:641–648.
   PubMed Web of Science ®Google Scholar
• Ericsson C-G, Nilsson J, Grip L, et al. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (the bezafibrate coronary atherosclerosis intervention trial [BECAIT]). Am J Cardiol. 1997 Nov;80:1125–1129.
   PubMed Web of Science ®Google Scholar
• Meade T, Zuhrie R, Cook C, et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ. 2002 Nov 16;325:1139.
   PubMed Web of Science ®Google Scholar
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the bezafibrate infarction prevention (BIP) study. Circulation. 2000 Jul 4;102:21–27.
   PubMed Web of Science ®Google Scholar
• Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005 May 23;165:1154–1160.
   PubMed Web of Science ®Google Scholar
• Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet Lond Engl. 2007 Nov 17;370:1687–1697.
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362:1563–1574.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) lipid trial: what we learn from subgroup analyses. Diabetes Care. 2011 May 1;34:S107–8.
   PubMed Web of Science ®Google Scholar
• Elam MB, Ginsberg HN, Lovato LC, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol. 2017 Apr 1;2:370–380.
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010 Jul 15;36:233–244.
   Google Scholar
• Steiner G, Hamsten A, Hosking J, et al. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet Lond Engl. 2001 Mar 24;357:905–910.
   Google Scholar
• Davidson MH, Rosenson RS, Maki KC, et al. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol. 2014;34:1298–1306.
   PubMed Web of Science ®Google Scholar
• Jakob T, Nordmann AJ, Schandelmaier S, et al. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev. 2016;11:CD009753.
   PubMedGoogle Scholar
• Scott LJ. Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency. Drugs. 2015 Feb;75:175–182.
   PubMed Web of Science ®Google Scholar
• Galán Carrillo I, Demelo-Rodriguez P, Rodríguez Ferrero ML, et al. Double filtration plasmapheresis in the treatment of pancreatitis due to severe hypertriglyceridemia. J Clin Lipidol. 2015 Sep;9:698–702.
   PubMed Web of Science ®Google Scholar
• Chaudhary A, Iqbal U, Anwar H, et al. Acute pancreatitis secondary to severe hypertriglyceridemia: management of severe hypertriglyceridemia in emergency setting. Gastroenterol Res. 2017 Jun;10:190–192.
   PubMed Web of Science ®Google Scholar
• Arai H, Yamashita S, Yokote K, et al. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis. 2017;261:144–152.
   PubMed Web of Science ®Google Scholar
• Blair HA. Pemafibrate: first global approval. Drugs. 2017 Sep 19;77:1805–1810.
   PubMed Web of Science ®Google Scholar
• Lazaridis N, Tsochatzis E. Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Rev Gastroenterol Hepatol. 2017 Apr 3;11:357–369.
   PubMed Web of Science ®Google Scholar
• Fruchart J-C. Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists. Cardiovasc Diabetol. 2013;12:82.
   PubMed Web of Science ®Google Scholar
• Joshi SR. Saroglitazar for the treatment of dyslipidemia in diabetic patients. Expert Opin Pharmacother. 2015 Mar;16:597–606.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Sahana PK, Das C, et al. Comparison of effectiveness and safety of add-on therapy of saroglitazar and fenofibrate with metformin in Indian patients with diabetic dyslipidaemia. J Clin Diagn Res JCDR. 2016 Mar;10:FC01–4.
   PubMed Web of Science ®Google Scholar
• Ishibashi S, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016;249:36–43.
   PubMed Web of Science ®Google Scholar
• Shetty SR, Kumar S, Mathur RP, et al. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients. Indian Heart J. 2015 Feb;67:23–26.
   PubMedGoogle Scholar
• Mudur G. Indian endocrinologists start debate on diabetes drug. BMJ. 2015 Sep 29;h5160.
   PubMedGoogle Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131.
   PubMed Web of Science ®Google Scholar